BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ishikawa T, Okoshi M, Tomiyoshi K, Kojima Y, Horigome R, Imai M, Nozawa Y, Iwanaga A, Sano T, Honma T, Yoshida T. Efficacy and safety of repeated use of lusutrombopag prior to radiofrequency ablation in patients with recurrent hepatocellular carcinoma and thrombocytopenia. Hepatol Res. 2019;49:590-593. [PMID: 30602063 DOI: 10.1111/hepr.13305] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Bankston PC, Al-Horani RA. New small molecule drugs for thrombocytopenia: chemical, pharmacological, and therapeutic use considerations. Int J Mol Sci. 2019;20:3013. [PMID: 31226783 DOI: 10.3390/ijms20123013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
2 Numata K, Tanaka K, Katsube T, Ochiai T, Fukuhara T, Kano T, Osaki Y, Izumi N, Imawari M. Is platelet monitoring during 7-day lusutrombopag treatment necessary in chronic liver disease patients with thrombocytopenia undergoing planned invasive procedures? A phase IIIb open-label study. Hepatol Res 2020;50:1141-50. [PMID: 32609920 DOI: 10.1111/hepr.13544] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Nishida Y, Kawaoka T, Imamura M, Namba M, Fujii Y, Uchikawa S, Ohya K, Daijo K, Teraoka Y, Morio K, Fujino H, Nakahara T, Yamauchi M, Hiramatsu A, Tsuge M, Aikata H, Takahashi S, Hayes CN, Fukuhara T, Tsuji K, Arataki K, Nagaoki Y, Aisaka Y, Kamada K, Kodama H, Chayama K. Efficacy of Lusutrombopag for Thrombocytopenia in Patients with Chronic Liver Disease Scheduled to Undergo Invasive Procedures. Intern Med 2021;60:829-37. [PMID: 33087674 DOI: 10.2169/internalmedicine.5930-20] [Reference Citation Analysis]
4 Kawaratani H, Tsuji Y, Ishida K, Kaya D, Kubo T, Fujinaga Y, Sawada Y, Sato S, Takaya H, Kaji K, Namisaki T, Moriya K, Akahane T, Yoshiji H. Effect of three or more treatments with lusutrombopag in patients with cirrhotic thrombocytopenia: A retrospective single-center study. Hepatol Res 2020;50:1101-5. [PMID: 32558192 DOI: 10.1111/hepr.13536] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Wada N, Uojima H, Satoh T, Okina S, Iwasaki S, Shao X, Takiguchi H, Arase Y, Itokawa N, Atsukawa M, Miyazaki K, Hidaka H, Kako M, Kagawa T, Iwakiri K, Horie R, Suzuki T, Koizumi W. Impact of Anti-GPIIb/IIIa Antibody-Producing B Cells as a Predictor of the Response to Lusutrombopag in Thrombocytopenic Patients with Liver Disease. Dig Dis 2021;39:234-42. [PMID: 32759604 DOI: 10.1159/000510692] [Reference Citation Analysis]
6 Turco L, de Raucourt E, Valla DC, Villa E. Anticoagulation in the cirrhotic patient. JHEP Rep 2019;1:227-39. [PMID: 32039373 DOI: 10.1016/j.jhepr.2019.02.006] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 9.0] [Reference Citation Analysis]
7 Nomoto H, Morimoto N, Miura K, Watanabe S, Takaoka Y, Maeda H, Sasaki T, Koyashiki Y, Kurata H, Numao N, Isoda N, Yamamoto H. Lusutrombopag is effective and safe in patients with chronic liver disease and severe thrombocytopenia: a multicenter retrospective study. BMC Gastroenterol 2020;20:427. [PMID: 33317473 DOI: 10.1186/s12876-020-01573-9] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Yoshiji H, Ueno Y, Kurosaki M, Torimura T, Hatano E, Yatsuhashi H, Yamakado K. Treatment algorithm for thrombocytopenia in patients with chronic liver disease undergoing planned invasive procedures. Hepatol Res 2021;51:1181-95. [PMID: 34555262 DOI: 10.1111/hepr.13715] [Reference Citation Analysis]
9 Qureshi K, Bonder A. Thrombopoietin-receptor agonists in perioperative treatment of patients with chronic liver disease. World J Meta-Anal 2020; 8(3): 220-232 [DOI: 10.13105/wjma.v8.i3.220] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Chen F, McDonald V, Newland A. Experts' review: the emerging roles of romiplostim in immune thrombocytopenia (ITP). Expert Opin Biol Ther 2021;:1-11. [PMID: 34313512 DOI: 10.1080/14712598.2021.1960979] [Reference Citation Analysis]
11 Sasaki R, Shiino C, Imawari M, Bentley R, Cai B, Yoshida M, Afdhal N. Safety and effectiveness of lusutrombopag in Japanese chronic liver disease patients with thrombocytopenia undergoing invasive procedures: Interim results of a postmarketing surveillance. Hepatol Res 2019;49:1169-81. [PMID: 31228221 DOI: 10.1111/hepr.13392] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
12 Ishikawa T, Okoshi M, Tomiyoshi K, Kojima Y, Horigome R, Imai M, Nozawa Y, Iwanaga A, Sano T, Honma T, Yoshida T. Efficacy and safety of repeated use of lusutrombopag prior to radiofrequency ablation in patients with recurrent hepatocellular carcinoma and thrombocytopenia. Hepatol Res. 2019;49:590-593. [PMID: 30602063 DOI: 10.1111/hepr.13305] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]